Y-Biologics

Y-Biologics, Inc., an antibody therapeutics development company provides the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers.

Its portfolio also includes AR166, AR169, and AR170 for solid cancers, and AR153, a pH-dependent antibody for the treatment of solid cancer. Incorporated in 2007, Y-Biologics is headquartered in Daejeon, South Korea.